Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Melanoma, Cutaneous Malignant
Interventions
IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
Biological · Drug
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Conditions
Cutaneous Melanoma, Synovial Sarcoma
Interventions
IMA203, mRNA-4203
Biological
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Interventions
IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect®
Biological · Drug · Device
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Miami, Florida + 8 more